Will lung cancer recur? A genetic test may provide the answer

May 19, 2008

The goal of developing reliable genetic tests to guide lung cancer treatment has taken a step forward. Researchers at Columbia University recently evaluated the ability of five high-risk genetic profiles, or signatures, to predict the likelihood that cancer would recur in patients whose non-small cell lung cancer was caught early and surgically removed. They will present their findings at the American Thoracic Society’s 2008 International Conference in Toronto on Tuesday, May 20.

“Non-small cell lung cancer, which accounts for about 80 percent of all lung cancers, has a high rate of recurrence even when treated early,” said lead researcher William Bulman, M.D. “If we knew specifically in which patients the cancer was likely to come back, we could recommend more aggressive therapy to those patients.” Dr. Bulman noted that genetic signatures for breast cancer are already commercially available and are used by physicians to guide treatment recommendations.

Dr. Bulman and his colleagues, Drs. Charles Powell and Alain Borczuk, tested five survival gene signatures in 21 patients, with squamous or adenocarinoma tumors who were followed for up to two years after their surgery. The accuracy of the tested signatures ranged from 40 to 80 percent and varied with the type of tumor. A 42-gene signature, for instance, was 82 percent accurate in predicting survival with lung adenocarcinoma, but only 70 percent accurate in predicting survival with squamous cell carcinoma.

“Lung cancer is a heterogeneous disease, and information captured in these tests helps to distinguish tumors in terms of clinical outcomes.” explained Dr. Bulman. “Our findings not only indicate that genetic signatures have clinical utility in personalizing the treatment of lung cancer, but also that it may be necessary to use different gene-based risk predictors with different tumor subtypes.”

Dr. Bulman noted that this research is part of a larger effort to understand the biological basis for why some early stage lung cancers progress and metastasize and why some do not. He added that he and his colleagues are planning to test these genetic signatures in new cohorts of patients for the purposes of targeting patients at high risk for recurrence.

Source: American Thoracic Society

Explore further: Immunotherapy could stop resistance to radiotherapy

add to favorites email to friend print save as pdf

Related Stories

Researchers find genetic marker for repeat lung cancer

Aug 19, 2010

Current lung cancer survival statistics present a grim prognosis, but new findings could greatly impact survival rates. Researchers led by Lan Guo, Ph.D. at the West Virginia University Mary Babb Randolph Cancer Center have ...

Recommended for you

Study pinpoints microRNA tied to colon cancer tumor growth

6 hours ago

Researchers at the University of Minnesota have identified microRNAs that may cause colon polyps from turning cancerous. The finding could help physicians provide more specialized, and earlier, treatment before colon cancer ...

Obesity tied to higher cancer risk for CRC survivors

7 hours ago

(HealthDay)—Colorectal cancer (CRC) patients who are overweight or obese when diagnosed appear to face a slightly higher risk for developing a second weight-related cancer, according to research published ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

gdpawel
not rated yet May 21, 2008
Hopefully, Columbia University's genetic test will go the same way as the Lung Metagene Predictor in telling physicians which high risk lung cancer patients will likely benefit from chemotherapy (identify patients who are likely to have a recurrence if treated with surgery alone) and which ones do not need to be unnecessarily exposed to toxic chemotherapy cocktails.

The Lung Metagene Predictor is a genetic analysis that scans thousands of genes to identify patterns of gene activity in individual tumors that indicate a patient is likely to suffer a recurrence of disease. It is based on RNA microarry analysis and is an appropriate application of a genomic strategy to estimate prognosis, by identifying early stage cancer patients who may benefit from adjuvant chemotherapy.

If these genetic tests find a patient to be at "high" risk, then a suitable platform can be used to utilize in vitro chemoresponse assays to better select a repertoire of available drugs to improve the efficacy of chemotherapy. None of the genetic tests can predict clinical responders. Further pre-tests can help see what treatments have the best opportunity of being successful.

All of these laboratory tests are used as a tool for the oncologist. The oncologist should take advantage of all the tools available to him/her to treat a patient. These tests have enormous implications for the short-term future of cancer research in general, and is one of the truly great cancer breakthroughs of our time. DNA microarray will prove to be highly complementary to the parellel breakthrough efforts in targeted therapy through oncologic in vitro chemoresponse assays.